LV13268B - Novel boronate esters - Google Patents
Novel boronate esters Download PDFInfo
- Publication number
- LV13268B LV13268B LV040105A LV040105A LV13268B LV 13268 B LV13268 B LV 13268B LV 040105 A LV040105 A LV 040105A LV 040105 A LV040105 A LV 040105A LV 13268 B LV13268 B LV 13268B
- Authority
- LV
- Latvia
- Prior art keywords
- formula
- compound
- aryl
- aralkyl
- alkyl
- Prior art date
Links
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to optically active dihydroxy hexanoate derivatives, boronate esters of formula (IIa) which are useful intermediates for the synthesis of HMG-CoA enzyme inhibitors like atorvastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin. Ar = unsubstituted or substituted aryl or heteroaryl; R3 = alkyl from 1 to 8 carbons, aryl or aralkyl; R4 = O, OH, CN or a halogen and a =single bond or a double bond.
Description
LV 13268
TITLE OF THE INVENTION
Novel Boronate esters
FĪELD OF THE INVENTION 5 The present invention relates to optically active dihydroxy hexanoate derivatives of formula Ila and more particularly to compounds of formula II which are useful intermediates for the synthesis of HMG-CoA enzyme inhibitors like atorvastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin.
BACKGROUND OFTHE INVENTION
Esters and derivatives of the formula 1, or, or2 HO-^A^C°2R3 where Ri and R2 are independently chosen alkyl of one to three i5 carbons and R3 is alkyl of from 1 to 8 carbon atoms, alternatively compounds of formula la,
vvherei'n Ri and R2 are independently chosen from alkyl of one to three carbons, phenyl or Rt and R2 taken together as -(CH2)n- vvherein 2o n is 4 or 5 and R3 is alkyl of from 1 to 8 carbon atoms and also compounds of Formula lb R1 R2
I I
wherein Ri and R2 are alkyl of from 1-5 carbons and R3 is as defined above is a valuable structural element for synthesizing compounds, which are known as anti-hypercholesterolemic aģents having an inhibitory effect on HMG-CoA reductase. EP 0 319 847 describes a process for the preparation of compounds of formula 1 starting from L-Malic acid. This process, however, suffers from the fact that the process is not industrially scalable and aiso possesses purification problems due to the non-io crystailine nature of the intermediates. US 5,399,722 describe a process starting from commercially available ethyl ω-cloroacetoacetate or its benzyloxy derivative. The disadvantages of this process are that a stereo selective reduction using a costly ruthenium-BINAP cata!yst in employed and the desired i5 compound of formula 1 is obtained in six steps. US 5,481,009 describe a process starting from 4-phenyl-3-butenoic acid in about 5 steps. The process uses expensive materiāls like - N, 0-Dimethyl hydroxylamine and hazardous steps (ozonolysis) to obtain the desired product. ) US 5,998,633 describes a process for the preparation of protected esters of 3,4-dihydroxy butyric acid from a carbohydrate moiety which is transformed into the desired 3,4-dihydroxy butanoic acid derivatives in about 4 steps. The 3,4-dihydroxy butanoic acid 2 LV 13268 derivative is then functionalized into compounds of formula I involving a multiple number of steps. 2( US 6,140,527 describes a process for producing butyric acid derivatives starting from a butene derivative follovved by reaction with an addition reaģent capable of adding across the double bond. Hovvever, this procedure does not afford chiral molecules and hence necessitates the need for a resolution step. EP 0 104 750 describes a process for the preparation of 5-hydroxy-3-oxo pentanoic acid derivatives by alkylation of 3-īo hydroxybutyrate derivatives. The derivatives mentioned in this patent are racemic molecules and thus necessitating a resolution step.
The objective of the present is to provide a simple and industrial!y scalable process for the preparation of derivatives of formula I starting from commercially available and inexpensive malic acid. 15 LV 13268
Summary of the invention
To achieve the said object the present invention provides a product of formula Ila and more particularly a compound of formula II
Ar
a
Formula Ila 3 0
HO
°s P
B
Ar
Formula II vvherein
Ar = unsubstituted or substituted aryl or heteroaryl R3 = alkyl from 1 to 8 carbons, aryl or aralkyl R4 = 0, OH, CN or a halogen and a = single bond or double bond
The present invention also provides for a process for the manufacture of compounds of formula II H0 'Ύ'ΎΎ0 ^ fi 0
B
I
Ar
Ar = unsubstituted or substituted aryl or heteroaryl R3 = alkyl from 1 to 8 carbons, aryl or aralkyl which comprises of: (a) reacting compound of formula III with the anion of tertiary butyl acetate to give a compound of formula IV, vvhere G is tetrahydropyranyl, tert-butyldimethyl silyl or trityl and R3 is io alkyl from 1 to 8 carbons, aryl or aralkyl,
o o Formula III
0 0 0 Formula IV (b) subjecting compound of formula IV to reduction to give a iī compound of formula V, where G is tetrahydropyranyl, tert- butyldimethyl silyl or trityl and R3 is alkyl from 1 to 8 carbons, aryl or aralkyl,
0 0 0 Formula V 5 LV 13268 (c) protecting the compound of formula V vvith ArB(OH)2 to give a compound of formula VI, vvhere Ar is unsubstituted or substituted aryl or heteroaryl, G is tetrahydropyranyl, tert-butyldimethyl silyl or trityl and R3 is alkyl from 1 to 8 carbons, aryl or aralkyl, and 20 5 GO/YYY°'r3 0γ° ° i
Ar
Formula VI (f) deprotection of the compound of formula VI using mild acid catalyst to give a compound of formula II. 10
Said ArB(OH)2 is boronic acid.
The compound of formula II is oxidized to a compound of formula VIII, vvhere R3 is alkyl from 1 to 8 carbons, aryl or aralkyl and i> Ar is unsubstituted or substituted aryl or heteroaryl using pyridinium chloro chromate or DMSO/oxalyl chloride.
Ar
I
Formula VIII
The compound of formula II is further converted to a compound of formula IX, vvhere R3 is a!kyl from 1 to 8 carbons, aryl or aralkyl, Ar is unsubstituted or substituted aryl or heteroaryl and X is a halogen. 6 X^W "R3 V* ° i
Ar
Formula IX :0
The compound of formula IX is further converted to a compound of formula VII, where R3 is alkyl from 1 to 8 carbons, aryl or aralkyl, Ar 5 is unsubstituted or substituted aryl or heteroaryl.
Ar
I
Formula VII
The product of formula Ila and more particularly of formula II are used in the synthesis of atorvastatin, cerivastatin, pitavastatin, ī- fluvastatin or rosuvastatin.
Detaiied Description of the inventīon
Compound of formula II serves as a good intermediate for the synthesis of important substrates, which are useful in the synthesis of statins. Compound of formula II can be converted into a facile leaving i5 group by treating vvith tosyl chloride, methane sulfonyl chloride and the resulting intermediate can be displaced vvith cyanide to give compounds of formula VII.
Compound of formula II can be converted to formula IX by reacting vvith aqueous HBr solution or by reaction vvith triphenyl 20 phosphine and CBr4 vvhich is then converted to compound of formula VII. 7 LV 13268
Compound of formula II can be oxidized using Standard procedures to give a compound of formula VIII.
The present invention relates to optically active dihydroxy hexanoate derivatives of formula Ila which are useful intermediates for 5 the synthesis of HMG-CoA enzyme inhibitors like atorvastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin.
The invention is further illustrated with examples below, which are not intended to be limiting.
Example 1: Synthesis of methyl 4-triphenylmethyloxy-3-hydroxybutyrate (Formula IIī)
To 25g of methyl 3,4-dihydroxybutanoate was added to 250ml of DCM and stirred to dissolve and 19.8g of pyridine was charged and 5 cooled to 0°C. 41.4g of trityl chloride was dissolved in 50ml of DMC and was added at 0-5°C for 15 min. The temperature was allowed to rise to RT and was stirred at RT for 17h. Water was added and the layers were separated. The organic layer was washed with brine, dried and concentrated. The residue was triturated with 25ml of cyclohexane and the product was purified to give 15g of the pure product. NMR (CDCI3) : 4.25 (m, 1H), 3.6 (s, 3H), 3.15 (d, 2H), 2.5 (m, 2H), 7.2-7.4 (m, 15H)
Example 2: Synthesis of tert-butyl 6-triphenylmethyloxy-5-hydroxy-3-oxohexanoate (Formula IV) 5 To 125ml of THF, 24g of diisopropylamine were charged and was cooled to -15°C. 168ml of 1.2N n-BuLi was added at -15 to -5°C and 8 0 was stirred for 30min. 21.56g of tert-butyl acetate in 45ml of THF which was pre-cooled to -45°C was added maintaining the temperature betvveen -45 to -25°C for 60min. Cool the reaction mixture to -45°C and 30g of example-l in THF was added over a period of 20min and 5 the stirring was continued at -25°C for 90min. Water was added and the layers were separated. The aqueous layer was extracted using EtOAc and the combined organic layers were washed with brine, vvater, dried and concentrated to give the title compound vvhich was used as such for the next step. it Example 3: Synthesis of tert-butyl β-ΐπρΗβηγΙηιβίΙιγΙοχγ^,Β-dihydroxhexanaote (Formula V)
To the crude material obtained in example-2,150ml of THF was added follovved by 15ml of MeOH and was chiiled to -60°C. 26ml of MDEB (50% solution in THF) was added over a period of 20min and i5 stirring was continued for a further 30min. The reaction mixture was cooled to -80°C and 5g of sodium borohydride was added in portions and the after compietion of addition the reaction mixture was stirred for 5h at -78°C. Acetic acid was added to adjust the pH to 7 and vvater was added. The aqueous layer was extracted using EtOAc, vvashed 20 with brine, dried and concentrated to give the title compound vvhich was used as such for the next step.
Example 4: Synthesis of tert-Butyl 6-triphenylmethyloxy-3,5-phenylboranatohexanoate (Formula VI)
The crude product from example-3 was dissolved in lOOml of toluene and 5.6g of phenyl boronic acid was added. Water was 9 LV 13268 removed by azeotropic distillation over a period of 3h. The reaction mixture was cooled to RT and toluene was removed under reduced pressure. 30ml of methanol was added and the precipitated solid was filtered to give lOg of the title product.
Example 5: Synthesis of tert-butyl 6-hydroxy-3,5-23 (phenylboranato)hexanoate (Formula II)
To 5g of the product from example-4 20ml of DCM was added and was chilled to 0°C. 5ml of TFA was added and was stirred at 20°C for 6h. Water was separated and the organic layer was vvashed with io bicarbonate, brine, dried and concentrated to give the title product, vvhich was purified by column chromatography. NMR (CDCI3) : 7.7-7.8 (m, 2H), 7.4-7.5 (m, 1H), 7.3-7.4 (m, 2H), 4.5 (m, 1H), 4.2 (m, 1H), 3.6 (m, 1H), 3.5 (m, 1H), 2.55 (m, 1H), 2.45 (m, 1H), 2.0 (m, 1H), 1.7 (m, 1H) 1.5 (s, 9H) 1 Example 6: Synthesis of tert-butyl 6-cyano-3,5-(phenylboranato)hexanoate (Formula VII) 5g of the product obtained from example 5 was taken in dichloromethane (50mL) and pyridine (lOmL) was added. The contents were cooled to -10°C and methanesulfonyl chloride (1 eq) was added 20 drop wise. After 5-6 hours of stirring at 0°C, the contents were washed with bicarbonate, water and brine. The solvent was removed under reduced pressure to afford the 0-methanesulfonyl derivative, which was used as such for the next step.
The crude mesylate was taken in DMSO (5 vols.) and 1.5 25 eguivalents of potassium cyanide was added. The contents were 10 maintained at reflux for a period of 18-22h. DMSO was removed under reduced pressure and the contents were extracted using ethyl acetate and was washed with bisulfite, brine and solvent was removed under reduced pressure to afford the desired product.
Example 7: Synthesis of t-butyl 6-oxo-3,5-phenylboranatohexanoate (Formula VIII) 4.3g of dimethylsulfoxide was added drop wise to a solution of 2.4ml of oxalyl chloride in lOOml of dichloromethane maintained at -78°C. The mixture was stirred at that temperature for a period of 15min and 5g of the compound from example 5 dissolved in dichloromethane was added drop wise. After stirring for 15min, 17ml of triethyl amine was added and the reaction mixture was allowed to warm to ambient temperature in 2h period. Reaction mixture was concentrated and the residue was dissolved in water and extracted using diethyl ether. Removal of solvent affords the title compound.
Example 8: Synthesis of tert-butyl 6-triphenylmethyloxy-3,5-(l-napththalenyl)boranatohexanoate (Formula Via)
The crude product from example-3 was dissolved in 100 ml of toluene and 7.1 g of 1-napthalene boronic acid was added. Water was removed by azetropic distillation over a period 3h. The reaction mixture was cooled to RT and toluene was removed under reduced pressure.30ml of methanol was added and the precipitated solid was filtered to give 14g of the title product. 11 LV 13268
Example 9: Synthesis of tert-butyl 6-triphenylmethyloxy-3,5-(2-methylphenyl)boranatohexanoate (Formula VIb) 5 The crude production from example-3 was dissolved in lOOml of toluene and 6.1g of 2-methylphenyl boronic acid was added. Water was removed by azetropic distillation over a period of 3h. The reaction mixture was cooled to RT and toluene was removed under reduced pressure. 30ml of methanol was added and the precipitated solid was ! filtered to give 12g of the title prodiiGt.
Example 10: Synthesis of tert-butyl 6-triphenylmethyloxy-3,5-(4-methoxyphenyl)boranatohexanoate (Formula Vīc)
The crude product from example-3 was dissolved in lOOml of toluene i5 and 6.3 g of 4-methoxyphenyl boronic acid was added. Water was removed by azetropic distillation over a period of 3h. The reaction mixture was cooled to RT and toluene was removed under reduced pressure. 30ml of methanol was added and the precipitated solid was filtered to give 12g of the title product. 20
Example 11: Synthesis of tert-butyl 6-triphenylmethyloxy-3,5-(8-quinolinyl)boranatohexanoate (Formula Vlf)
The crude product from example-3 was dissolved in lOOml of toluene and 6.1g of quinoline-8-boronic acid was added. Water was removed by azetropic distillation over a period of 3h. The reaction mixture was 12 cooled to RT and toluene was removed under reduced pressure. 30ml of methanol was added and the precipitated solid was filtered to give llg of the title product. s Example 12: Synthesis of tert-butyl 6-triphenylmethyloxy-3,5-73 (3-nitrophenyl)boranatohexanoate (Formula Vīd)
The crude product from example-3 was dissolved in lOOml of toluene and 6.1 g of 3-nitrophenyl boronic acid was added. Water was removed by azetropic distillatlon over a period of 3h. The reaction io mixture was cooled to RT and toluene was removed under reduced pressure. 30ml of methanol was added and the precipitated solid was filtered to give lOg of the title product.
Example 13: Synthesis of tert-butyl 6-triphenylmethyloxy-3,5-(2,6-difluorophenyl)boranatohexanoate (Formula VIe)
The crude product from example-3 was dissolved in lOOml of toluene and 6.3 g of 2,6-difluorophenyl boronic acid was added. VVater was removed by azetropic distillation over a period of 3h. The reaction mixture was cooled to RT and toluene was removed under reduced ίο pressure. 30ml of methanol was added and the precipitated solid was filtered to give 12g of the title product.
S 13 LV 13268
Formula I Formula lb OR, or2 R1 R2 i i. Η0\^^^\/002Κ3 R1 and R2 are alkyl 1 to 3 carbons Siv, ^si H0'^^'n^V^C02R3 R3 is alkyl from 1 to 8 carbons R1 and R2 are alkyl from 1 to 5 carbons R 3 is alkyl from 1 to 8 carbons Formula la Formula Ila r1n/R2 Ar 1 0 0 H0\^\^\/C02R3 0 0 C02R3 a R1 and R2 are alkyl 1 to 3 carbons or taken together as -(CH2)n- where n is 4 or 5 R3 is alkyl from 1 to 8 carbons Ar = unsubstituted or substituted aryl or heteroaryl R3 = alkyl from 1 to 8 carbons, aryl or aralkyl R4 = OH, CN or X and a =singie bond R4 = 0 and a = double bond Formula II Formula III H0>"YYY0'R3 P 0 B I o o 1 Ar Ar = Unsubstituted or substituted aryi or heteroaryl and R3 is carbon from 1-8 atoms, aryi or aralkyl G = tetrahydropyranyi, tert-butyidīmethyl silyl, trityl Formula IV Formula V 0 0 0 S'0'^T^V^T°'R3 0 0 0 G = tetrahydropyranyl, tert-butyldimethyl silyl, trityl and R3 = alkyl from 1 to 8 carbons, aryl or aralkyl G = tetrahydropyranyl, tert-butyldimethyl sily1, trityl and R3 = alkyl from 1 to 8 carbons, aryl or aralkyl Formula VI Formula VII “'"ΎΤΎ0'” Ar 1 o co—< / O /Dv 0 0 G = tetrahydropyranyl, tert-butyldimethyl silyl, trityS and Ar = Unsubstituted or substituted aryl or heteroaryl and R3 is carbon from 1-8 atoms, aryi or aralkyl Ar = Unsubstituted or substituted aryl or heteroaryl and R3 is carbon from 1-8 atoms, aryi or aralkyl 14
15 LV 13268
16
Scheme -1 ΎΎ °v/- G- o o
“ΎΎΥ' 0 0 0 IV R3
Scheme - 2 ' G'°^rrV'-0 0 0
IV
Scheme - 3
°ΎΥΥ°' O O 0 V 6'0'^N/V'°'R3
ArB(OH), R3
0 O O V
I Ar VI
Scheme - 4
Ar VI Η°'^Νγ^Ννγ^γ°·'ρ3 °N o
B .0
Scheme - 5
°N 0 B Ar Χ'~Υ'Ύ~Υ S> 0 B Ar
IX ov R3 17 LV 13268
Seheme - 6
x'TYY°'R3 ^ 0 B I _„ ^τγγ0'»3 °v° 0 I I Ar IX I Ar VII Seheme - 7 <\ 0 B I °*;Y"Y''Y0'R3 o. /) 0 B I I Ar II I Ar VIII
ĪS LV 13268
We claim: 1. The product of formula Ila
Ar I
a vvherein
Ar = unsubstituted or substituted aryl or heteroaryl R3 = alkyl from 1 to 8 carbons, aryl or aralkyl R4 = Ο, OH, CN or a halogen and 10 a = single bond or double bond
2. The product as claimed in claim 1 vvherein said product is a compound of formula II
HO γ γ Y °s P °
B
I
Ar 15 wherein
Ar = unsubstituted or substituted aryl or heteroaryl R3 = alkyl from 1 to 8 carbons, aryl or aralkyl 19
3.1 A process for the manufacture of compounds of formula II
°s fi 0 B
Ar
Ar = unsubstituted or substituted aryl or heteroaryl R3 = alkyl from 1 to 8 carbons, aryl or aralkyl 5 which comprises of: (a) reacting compound of formula III with the anion of tertiary butyl acetate to give a compound of formula IV, where G is tetrahydropyranyl, tert-butyldimethyl silyl or trityl and R3 is alkyl from 1 to 8 carbons, aryl or aralkyl,
o o Formula III
0 0 0 Formula IV 15 (b) subjecting compound of formula IV to reduction to give a compound of formula V, where G is tetrahydropyranyl, tert-butyldimethyl silyl or trityl and R3 is alkyl from 1 to 8 carbons, aryl or aralkyl,
G
0 0 0 Formula V
2C ( c) protecting the compound of formula V with ArB(OH)2 to give a compound of formula VI, vvhere Ar is unsubstituted or 20 LV 13268 ‘ substituted aryl or heteroaryl, G is tetrahydropyranyl, tert-“ butyldimethyl silyl or trityl and R3 is alkyl from 1 to 8 carbons, aryl or aralkyl, and β'°ΎϊΎ°'-
°V° o I
Ar
5 Formula VI (f) deprotection of the compound of formula VI using mild acid catalyst to give a compound of formula II. 4. A process as claimed in claim 3 wherein ArB(OH)2 Is boronic acid. 5. A process as claimed in claim 3 vvherein compound of formula II is oxidized to a compound of formula VIII, where R3 is alkyl from 1 to 8 carbons, aryl or aralkyl and Ar is unsubstituted or substituted aryl or heteroaryl using pyridinium chloro chromate or DMSO/oxalyl chloride.
Ar
I
Formula VIII 6. A process as claimed in claim 3 wherein compound of formula II is further converted to a compound of formula IX, vvhere R3 is alkyl 20 from 1 to 8 carbons, aryl or aralkyl, Ar is unsubstituted or substituted aryl or heteroaryl and X is a halogen. 21 '0 *^rr0'-ον 0
I
Ar
Formula IX 7. A process as claimed in claim 6 vvherein compound of formula II is converted to compound of formula IX by reacting compound of formula II vvith aqueous HBr solution or by reaction with triphenyl phosphine and CBr4. 8. A process as claimed in claim 6 or 7 vvherein compound of io formula IX is further converted to a compound of formula VIĻ vvhere R3 is alkyl from 1 to 8 carbons, aryl or aralkyl, Ar is unsubstituted or substituted aryl or heteroaryl.
Ar
I 0 0 NCN^\/^\/C02R3
Formula VII i: 9. The product as claimed in claim 1, used in the synthesis of atorvastatin, cerivastatin, pitavastatin, fluvastatin or rosuvastatin. 22 5 LV 13268
ABSTRACT
The present invention relates to optically active dihydroxy hexanoate derivatives, boronate esters of formula Ila which are useful intermediates for the synthesis of HMG-CoA enzyme inhibitors like atorvastatin, cerivastatin, rosuvastatin, pltavastatin, fluvastatin. o
a'
Ar = unsubstituted or substituted aryl or heteroaryl R3 = alkyl from 1 to 8 carbons, aryl or aralkyl R4 = 0, OH, CN or a halogen and a =single bond or a double bond 23
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LV040105A LV13268B (en) | 2004-08-27 | 2004-08-27 | Novel boronate esters |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LV040105A LV13268B (en) | 2004-08-27 | 2004-08-27 | Novel boronate esters |
Publications (1)
Publication Number | Publication Date |
---|---|
LV13268B true LV13268B (en) | 2005-07-20 |
Family
ID=35745303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LV040105A LV13268B (en) | 2004-08-27 | 2004-08-27 | Novel boronate esters |
Country Status (1)
Country | Link |
---|---|
LV (1) | LV13268B (en) |
-
2004
- 2004-08-27 LV LV040105A patent/LV13268B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003218994B2 (en) | Process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivatives | |
EP1478650B1 (en) | Novel boronate esters | |
WO2003018555A1 (en) | Process for the preparation of indole derivatives | |
JPWO2017057642A1 (en) | Process for producing optically active 2- (2-fluorobiphenyl-4-yl) propanoic acid | |
Fabris et al. | The use of a lactonized statin side-chain precursor in a concise and efficient assembly of pitavastatin | |
van Kalkeren et al. | Protective group-free synthesis of 3, 4-dihydroxytetrahydrofurans from carbohydrates: formal total synthesis of sphydrofuran | |
WO2004113314A1 (en) | Novel boronate esters | |
JP5622019B2 (en) | Asymmetric organic molecular catalyst having amino alcohol derivative salt structure and method for producing optically active compound using said asymmetric organic molecular catalyst | |
CA2696195A1 (en) | Process for preparing pyrimidine derivatives | |
KR20080078127A (en) | Atorvastatin intermediates and method for producing the same | |
KR20130090360A (en) | Method for preparing compounds through a novel michael-addition reaction using water or various acids as additives | |
LV13268B (en) | Novel boronate esters | |
EP1631533B1 (en) | Novel process for stereoselective reduction of beta-ketoesters | |
JP5232989B2 (en) | Optically active 2,6-bisaminomethylpyridine derivative, production method thereof and use thereof | |
EP2679580A1 (en) | Thioamide compound, method for producing thioamide compound, method for producing [(4r,6r)-6-aminoethyl-1,3-dioxane-4-yl]acetate derivative, and method for producing atorvastatin | |
GB2075497A (en) | Preparation of tetra-substituted cyclopropane derivatives and intermediates therefor | |
RU2325393C2 (en) | Boronic acid ester and production method | |
ZA200406273B (en) | Novel boronate esters. | |
JP2940395B2 (en) | Preparation of oxyglutarate derivatives | |
JP2008068167A (en) | New chiral zirconium catalyst and manufacturing method of optical activity beta-aminocarbonyl compound using the same | |
JP2011184393A (en) | Optically active dicarboxylic acid derivative | |
PL208710B1 (en) | Novel boronate esters | |
CZ86799A3 (en) | Processes for preparing substituted derivatives of chromanol and intermediates for those processes | |
KR20080076124A (en) | Synthetic process of atorvastatin | |
JP2006328058A (en) | New method for producing 2-(1-benzothiophen-5-yl)ethanol and its intermediate |